Table 1.

CFTR modulators licensed for use in cystic fibrosis with a summary of the indications and jurisdictions with licensed approval

CFTR modulator	Mutation	Age group approved	Licensed approval
Ivacaftor	G551D*	≥2 years	US, Europe, Canada
		≥6 years	Australia, New Zealand
	R117H*	≥2 years	US
		≥18 years	Europe, Canada
	G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N, S549R*	≥2 years	US, Europe, Canada
		≥6 years	Australia
	G970R*	≥2 years	Canada
		≥6 years	Australia
Lumacaftor-ivacaftor	F508del homozygous	≥12 years	US, Europe, Canada

*At least one copy of the mutation.